Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
Go back to Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan| (NASDAQ: ACON) | Delayed: 2.74 -0.15 (5.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.89 | 52 Week High | $ | |||
| Open | $2.89 | 52 Week Low | $ | |||
| Day High | $2.92 | P/E | N/A | |||
| Day Low | $2.72 | EPS | $ | |||
| Volume | 151,082 | |||||
| (NASDAQ: ACONW) | Delayed: 0.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.03 | 52 Week High | $ | |||
| Open | $0.02 | 52 Week Low | $ | |||
| Day High | $0.03 | P/E | N/A | |||
| Day Low | $0.02 | EPS | $ | |||
| Volume | 29,262 | |||||
